Renal Disease (RUMP?) Robert Unwin University College London Matthew Bailey The University of Edinburgh.

Slides:



Advertisements
Similar presentations
1 Increasing Biotech Involvement in Global Health Innovation Oxford Conference on Innovation and Technology Transfer for Global Health September 11, 2007.
Advertisements

April 2010 MRC Data Sharing Policy Peter Dukes Policy Lead – Data Sharing & Preservation.
Chronic kidney disease
Chronic kidney disease
The National Kidney Foundations Kidney Early Evaluation Program TM The National Kidney Foundations Kidney Early Evaluation Program TM Essex-Passaic Wellness.
You have to provide a laboratory service for a Caucasian population of 3 million. How would you go about this? Describe your strategy for staff and equipment.
Diabetes, Anemia and Chronic Kidney Disease Josephine Carlos-Raboca,M.D., F.P.S.E.M., Endocrinology, Diabetes and Metabolism Makati Medical Center.
SOCIETY OF RENAL NUTRITION AND METABOLISM (SRNM)
Mayrene Hernandez, DO Advanced ProMed Inc. Billing and Management Solutions Board Certified in Family Medicine Clinical Assistant Professor for NSU.
Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.
Prepared by D. Chaplin Chronic Renal Failure. Prepared by D. Chaplin Chronic Renal Failure Progressive, irreversible damage to the nephrons and glomeruli.
Drug therapy in renal failure Kari Laine, MD, PhD University of Turku & medbase Ltd.
Cardiovascular and All-Cause Mortality Outcomes Among Hypertensive Patients With Moderate Renal Dysfunction in the ASCOT- LLA, and its.
Chromosome Disorders. Classification of genetic disorders  Single-gene disorders (2%)  Chromosome disorders (
Top 25 Universities Of The World (World University Rankings 2009) Top 25 Universities Of The World (World University Rankings 2009)
Understanding Diabetes Dr Gill Hood North Thames Clinical Research Network Barts Health NHS Trust
1º HARVARD UNIVERSITY - USA 2º UNIVERSITY OF CAMBRIDGE - UK.
Chronic Kidney Disease NICE Guidelines 2008 Dr Jennifer Kuo Dr Naeema Rashid Dr Shamita Das.
DEVELOPMENT OF STRATEGIES FOR PREVENTION OF CHRONIC KIDNEY DISEASE RELEVENT TO DIFFERENT REGIONS AND COUNTRIES ROBERT C ATKINS BELLAGIO, MARCH 2004.
Use of clinical laboratory databases to enable early identification of patients at highest risk of developing end- stage kidney disease Dr David Kennedy.
Renal Clearance The renal clearance of a substance is the volume of plasma that is completely cleared of the substance by the kidneys per unit time.
EPIDEMIOLOGY Epidemiology of chronic kidney injury, including prevalence and prognosis in various community groups. Screening of populations for kidney.
Improving Nephrology around the World March 16-18, 2004 ISN COMGAN Bellagio Conference Prevention of renal diseases in the emerging world: Toward global.
Unit 5 – Public Health Chronic Diseases
These slides were sponsored by Janssen and developed in conjunction with the BRS CKD Strategy Group, following an advisory board that was organised by.
2 December 2011 Renal Physiology
Techniques for Data Linkage and Anonymisation – A Funders View Turing Gateway Meeting 23 rd October 2014 Dr Mark Pitman.
TILDA and the HRB Professor Rose Anne Kenny Trinity College Mercers Institute St James Hospital.
The management of renal problems in primary care Hugh Gallagher Consultant Nephrologist St Helier Hospital.
MRC Mouse Network Jan 2012 Mouse eyes and vision research consortium Prof Marcela Votruba PhD FRCOphth Prof Ian Jackson PhD.
Renal failure. Pre-renal – disordered perfusion of a kidney which is structurally normal. Renal – damage to the renal parenchyma, sometimes secondary.
Public health research in Europe Mark McCarthy (University College London) Levels of health sciences molecules cells organs people populations Laboratory.
MRC Respiratory Development and Disease Consortium Dr Matt Hind and Dr Charlotte Dean National Heart and Lung Institute, Imperial College and MRC Harwell.
Presentation/Phenotype
MLAB 2401: Clinical Chemistry Keri Brophy-Martinez
Von Willebrand’s Disease (vWD) Among women with unexplained menorrhagia.
بسم الله الرحمن الرحيم. POLYCYSTIC KIDNEY DISEASE Lecture by: Dr. Zaidan Jayed Zaidan.
Renal Physiology and Function Part II Renal Function Tests
RaDaR – a national web based data collection for rare kidney diseases Moin Saleem – University of Bristol Mark Taylor – Birmingham Children’s Hospital.
Chronic Kidney Disease (CKD) Healthy Kansans 2010.
Foundation Doctors’ Academic Meeting Kathryn Adcock Wellcome Trust March 2011.
Ethics in Clinical Genetics and Genomics Key Knowledge Year 4 Medical Ethics and Law Thread Course, The Ethox Centre, University of Oxford.
Realising MRC’s Vision in Health and Bioinformatics MRC Open Council Meeting July 2014 Janet Valentine Head of Population Health and Informatics.
CLINICAL APPLICATION OF UREA MEASUREMENTS METABOLIC ASPECTS OF KIDNEY METABOLISM.
Wellcome Trust / Glaxo Smith Kline Translational Medicine Training Programme at Imperial College Dr Waljit Dhillo.
The future of the NIHR NIHR: 10 years of delivering health and care research for the nation QEII Centre, London Wednesday 18 May 2016 Professor Chris Whitty.
Careers in Academic Medicine A Personal Experience Duncan Bassett Clinical Senior Lecturer Molecular Endocrinology Group Imperial College London.
10 October 2016 Imperial College Wellcome Funding Opportunities Clare McVicker Research Careers
Institutional Strategic Objectives Performance
After Action Review EU Fundraising
Professor Chris Whitty CB FMedSci Chief Scientific Adviser
School for Primary Care Research
Slide presentation title to go here
UK Renal Registry 10th Annual Report 2007
Figure 26.1 An introduction to the Urinary System
Genomic Medicine Centre Overview
School for Primary Care Research
By Your Name Period X Biology 2005
Genomic Medicine Centre Overview
From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria  Paul E. De Jong, Barry M. Brenner  Kidney International 
Introduction to Research and Innovation at Leeds
School for Primary Care Research
Education Infographic
Genomic Medicine Centre Overview
Institutional Strategic Objectives Performance
Volume 62, Issue 4, Pages (October 2002)
Bio-Rad Overview and Statement of Interests
Generating reliable evidence on the determinants of NCDs
Urological cancer genomics
Presentation transcript:

Renal Disease (RUMP?) Robert Unwin University College London Matthew Bailey The University of Edinburgh

Network Rationale  ~10% of the UK population have chronic kidney disease (33% in over 65s)  Congenital renal disease in childhood  Increasing prevalence with rise in diabetes and metabolic disorders  Cyst disease main genetic cause of renal failure

Network Rationale  Human and economic burden large and often underestimated  Complex structure/function relationships  Renal phenotyping technically difficult  Time consuming and costly  Few Specialist Laboratories

Network overview Renal Disease Glomerular Tubular Development Cystic Renal Disease Glomerular Tubular Development CysticGlomerular: Bristol, Cambridge, Edinburgh, Imperial, Harwell, Oxford, UCL, Zurich Tubular: Cambridge, Edinburgh, Naples, Oxford, UCL, Zurich, Paris Cystic: Oxford, UCL, Naples, Zurich, Paris Development: Edinburgh, Harwell, Manchester, UCL We are: Clinical Scientists Physiologists Anatomists Human & Rodent Genetics

Network Activities Meeting in mid-April 2012 (London) Theme Leaders SOP for sample handling Curation (GUDMAP) Universal secondary screen or hypothesis- driven Discussion of gene selection

Universal secondary screens Radiotelemetry GFR in conscious mice Signal processing (Informatics) of Blood Flow Complementary in vitro screen (Oocytes) Image-based screening (sMRI fMRI) Specialist urine analysis

Discussion points Urine/tissue from primary screen Universal secondary screen desirable –Identification of Epistasis –Expensive (Strategic funding) –EP7 Rare Diseases and Omics- EURENOMICS Hypothesis-lead screening –Theme-based genes of interest –Incorporated into response mode function –Potentially less power for identifying novel function